Quanterix Corporation Announces the Addition of Dr. Robert Corn to its Scientific Advisory Board
Leader in single molecule detection to expand prominent Scientific Advisory Board
Dr. Corn added, "The novel technology platform being developed by Quanterix will provide medical researchers with a unique tool that allows low abundance biomarkers to be detected in complex biological samples. I am excited to join such a world class Advisory Board and look forward to working with the other members to further advance this promising technology."
Dr. Corn joins SAB members
Quanterix is developing a revolutionary Single Molecule Array (SiMoA(TM))
technology that allows the behavior of thousands of individual molecules to be
observed simultaneously, rather than an ensemble average of many molecules as
with existing technologies. Quanterix's platform will bring an unprecedented
level of sensitivity, precision, and assay robustness to clinical diagnostics,
drug development, and life science research. The first application that
Quanterix is pursuing with the SiMoA(TM) technology is the detection and
quantification of proteins present in blood and other body fluids at very low,
previously undetectable, concentrations. Diagnostic assays targeting proteins
that have been implicated in a variety of human diseases, including cancer,
chronic inflammatory disease and cardiovascular disease are under development.
Quanterix is a privately held company located in
SOURCE Quanterix Corporation
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.